Department of Oncology, Yijishan Hospital, First Affiliated Hospital of Wannan Medical College, Wuhu, China.
Department of Gastrointestinal Surgery, The Affiliated Hefei Hospital of Anhui Medical University, Hefei, China.
Bioengineered. 2022 Feb;13(2):2087-2098. doi: 10.1080/21655979.2021.2023796.
Breast cancer (BC) is a serious threat to female health. tRNA-derived fragments (tRFs) are popular biomarkers for the diagnosis and treatment of cancer. The purpose of this study was to identify tRFs related to BC and to explore the function and regulatory mechanism of crucial tRFs in BC cells. Small RNA database was used to detect the tRF profiles from BC patients and controls. Differentially expressed tRFs were determined by quantitative reverse transcription PCR (RT-qPCR), and a crucial tRF was evaluated through silence and overexpression experiments, and the target gene was investigated by luciferase reporter gene assay, Western blot and rescue experiment. We screened tRF-19-W4PU732S, which was processed from the mature tRNA-Ser-AGA, and significantly highlyexpressed in BC tissues and cells. Inhibition of tRF-19-W4PU732S weakened MDA-MB-231 cell proliferation, migration and invasion, while enhanced apoptosis. On the contrary, overexpression of tRF-19-W4PU732S promoted MCF-7 cell proliferation, migration and invasion, whereasreduced apoptosis. Furthermore, tRF-19-W4PU732S induced BC cell epithelial-to-mesenchymal transition (EMT) and cancer stem-like cells (CSC) phenotypes, such as up-regulation of OCT-4A, SOX2 and Vimentin and down-regulation of E-cadherin. Ribosomal protein-L27A (RPL27A) was a downstream target of tRF-19-W4PU732S, which was lowly expressed in BC cells. The knockdown of RPL27A expression partially restored the promoting effects of tRF-19-W4PU732S on BC cell viability, invasion, migration, EMT and CSC phenotypes, and the suppression of apoptosis. In conclusion, our results manifested that tRF-19-W4PU732S promotes the malignant activity of BC cells by inhibiting RPL27A, which provides a new scientific basis for the treatment of BC. BC: breast cancer; tRNAs: transfer RNAs; tiRNAs: tRNA-derived stressinduced RNAs; tRFs: tRNA-derived fragments; CCK-8: Cell Counting Kit-8; PI: propidium iodide; EMT: epithelial-to-mesenchymal transition; CSC: cancer stem-like cells; RPL27A: ribosomal protein-L27A; RT-qPCR: quantitative reverse transcription PCR.
乳腺癌(BC)是严重威胁女性健康的疾病。tRNA 衍生片段(tRFs)是癌症诊断和治疗的热门生物标志物。本研究旨在鉴定与 BC 相关的 tRFs,并探讨 BC 细胞中关键 tRFs 的功能和调控机制。使用小 RNA 数据库检测 BC 患者和对照者的 tRF 图谱。通过定量逆转录 PCR(RT-qPCR)确定差异表达的 tRFs,并通过沉默和过表达实验评估关键 tRF,通过荧光素酶报告基因检测、Western blot 和挽救实验研究靶基因。我们筛选出成熟 tRNA-Ser-AGA 加工的 tRF-19-W4PU732S,其在 BC 组织和细胞中显著高表达。抑制 tRF-19-W4PU732S 减弱了 MDA-MB-231 细胞的增殖、迁移和侵袭能力,同时促进了细胞凋亡。相反,过表达 tRF-19-W4PU732S 促进 MCF-7 细胞的增殖、迁移和侵袭,而降低了细胞凋亡。此外,tRF-19-W4PU732S 诱导 BC 细胞上皮间质转化(EMT)和癌症干细胞样细胞(CSC)表型,如上调 OCT-4A、SOX2 和波形蛋白,下调 E-钙黏蛋白。核糖体蛋白 L27A(RPL27A)是 tRF-19-W4PU732S 的下游靶标,在 BC 细胞中低表达。RPL27A 表达的敲低部分恢复了 tRF-19-W4PU732S 对 BC 细胞活力、侵袭、迁移、EMT 和 CSC 表型的促进作用,以及对细胞凋亡的抑制作用。综上所述,我们的研究结果表明,tRF-19-W4PU732S 通过抑制 RPL27A 促进 BC 细胞的恶性活性,为 BC 的治疗提供了新的科学依据。BC:乳腺癌;tRNAs:转移 RNA;tiRNAs:tRNA 衍生的应激诱导 RNA;tRFs:tRNA 衍生片段;CCK-8:细胞计数试剂盒-8;PI:碘化丙啶;EMT:上皮间质转化;CSC:癌症干细胞样细胞;RPL27A:核糖体蛋白 L27A;RT-qPCR:实时定量逆转录 PCR。